US FDA Approves Abiomed’s Impella For Cardiogenic Shock Ahead Of Schedule

US FDA has approved earlier than anticipated Abiomed’s Impella 2.5, Impella CP, Impella 5.0 and Impella LD transcatheter ventricular assist devices to provide treatment of ongoing cardiogenic shock.